Shanghai Henlius Biotech, Inc.
2696
Rankning i aktier
#4331
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise,... Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Aktiekurs
$6.69
Marknadsvärde
$3.65B
Förändring (1 dag)
1.85%
Förändring (1 år)
-28.81%
Land
CN
Handel Shanghai Henlius Biotech, Inc. (2696)
Kategori
Healthcare
EPS för Shanghai Henlius Biotech, Inc. (2696)
EPS per June 2026 TTM: $0.23
Enligt Shanghai Henlius Biotech, Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $0.23. Vid slutet av 2023 hade bolaget ett EPS på $0.14, en ökning jämfört med EPS från 2022 som var $-0.19.
EPS-historik för Shanghai Henlius Biotech, Inc. från 2017 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| 2026 (TTM) | $0.23 | 9.71% |
| 2024 | $0.21 | 44.99% |
| 2023 | $0.14 | -176.89% |
| 2022 | $-0.19 | -35.53% |
| 2021 | $-0.29 | 0.03% |
| 2020 | $-0.29 | 13.84% |
| 2019 | $-0.25 | 83.06% |
| 2018 | $-0.14 | 79.82% |
| 2017 | $-0.08 | 0.00% |
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $17.32 | 7,417.36% |
US
|
|
| $-7.98 | -3,563.54% |
US
|
|
| $-5.29 | -2,396.01% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 11,939.93% |
NL
|
